CCIT-DK - National Center for Cancer Immune Therapy of Denmark

CCIT-DK - National Center for Cancer Immune Therapy of Denmark at #ESMO24. Strong Presence of Our Team at the World's Leading Oncology Event - Marco Donia: Melanoma and Other Skin Tumors, Proffered Paper Session (Invited Discussant 1076O and 1082O) - Inge Marie Svane: Systemic treatment of anti PD-1 resistance in advanced melanoma, Educational Session (Cellular Therapies) - Eva Ellebæk (on behalf of Rikke Boedker Holmstroem and Danish Metastatic Melanoma Database (DAMMED): A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters (Poster, Melanoma and Other Skin Tumors) - Shawez Khan (on behalf of Danish Metastatic Melanoma Database (DAMMED): Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors (Poster, Melanoma and Other Skin Tumors) ESMO - European Society for Medical Oncology Edoardo Dionisio Perrine Verdys, PhD Shawez Khan Mario Presti Marta Sánchez Sánchez Anne Weiß Cecilie Dam Vestergaard

Our head of Cell Therapy Unit, Dr. Özcan Met at the ISCT, International Society for Cell & Gene Therapy Europe 2024 Meeting 👇

📣 Seminar: Epigenetic regulation of T cell adaptive immunity 👨⚕️ By Ben A. Youngblood 🕰 September 2nd 2024 at 14.00 📍 Auditorium H2, 3rd floor, Herlev Hospital, Copenhagen Area, Denmark. Maps at https://lnkd.in/dYZZSpMv 💻 Online attendance at: https://lnkd.in/ddHu5NNF ‼️ Join this seminar, No registration required ‼️ Benjamin Youngblood, PhD, is currently a member in the Department of Immunology at St. Jude Children's Research Hospital. He received a Bachelor of Science degree in Biochemistry from Oregon State University in 2001 and went on to do his graduate training in Biochemistry studying enzyme specificity of DNA methyltransferases at University of California Santa Barbara. He joined Professor Rafi Ahmed’s laboratory in 2007 for postdoctoral training focused on epigenetic regulation of memory CD8 T cell differentiation. In 2014, he joined the faculty at St. Jude Children's Research Hospital, and has developed a research program focused on epigenetic mechanisms involved in the development of functional and nonfunctional CD8 T cells, and translating novel discoveries into therapies that treat chronic viral infection, cancer, and autoimmunity.   Key Accomplishments Summary: Over the course of his scientific career his studies have broadly centered on the role DNA methylation plays in cellular differentiation. This focus started with his initial doctoral studies examining the enzymological determinates of DNA methyltransferase specificity, and gradually transitioned to studying specific changes in DNA methylation programming during in vivo T cell differentiation. As an independent investigator he has applied cutting-edge genome wide and single-cell epigenetic profiling approaches to assessing transcriptional regulation of genes that are critical in the development of functional and exhausted T cells generated in response to acute and chronic viral infections and tumors. He has previously reported that the development of functional versus exhausted antigen-specific CD8 T cells is coupled to the acquisition of distinct DNA methylation programs. His lab continues to investigate fundamental molecular mechanism(s) critical for development of long-lived memory CD4 and CD8 T cell functions. Moreover, his lab has established a robust research program investigating the role of epigenetic modifications in regulating T cell differentiation and how these programs affect the efficacy of T cell-based immunotherapy.     Organized by Inge Marie Svane

‼️Paper alert‼️ By Morten Orebo Holmström et al. (Mads Hald Andersen's team)

Updated Systematic Review and Meta-Analysis on TIL Therapy in Melanoma 👉 https://lnkd.in/d2kn789h (Silvia Martín Lluesma et al., Annals of Oncology, July 22nd 2024) 🔑 Key Findings: 1️⃣ Survival Outcomes: No significant difference in median overall survival (OS) after TIL therapy between patients who received prior anti-PD-(L)1 therapy and those who did not (17.5 vs. 16.3 months). 2️⃣ Response Rates: The objective response rate (ORR) was 34% for patients with prior anti-PD-(L)1 treatment and 44% for anti-PD-(L)1 naïve patients. The complete response rate was consistent at 10% across both groups. 3️⃣ Durability of Response: The median duration of response (DOR) to TIL therapy was 21 months for anti-PD-(L)1 naïve patients and 11.2 months for those with prior anti-PD-(L)1 treatment. No statistically significant differences in DOR were found. 🏥 Clinical Implications: ✅ TIL therapy remains a valuable option for patients with advanced cutaneous melanoma, particularly for those who have progressed after prior anti-PD-(L)1 treatment. ✅ TIL therapy has the potential to induce durable responses, even in heavily pretreated patients. 🔬 Further research is needed to explore the optimization of TIL therapy as a frontline treatment in the current era. 📄 The study analyzed data from 13 clinical trials involving 617 patients treated with TIL therapy over two decades. The director of CCIT-DK - National Center for Cancer Immune Therapy of Denmark, Inge Marie Svane, contributed as co-first author to this important article, highlighting the efficacy of TIL therapy in treating advanced cutaneous #melanoma. #TIL #celltherapy #immunotherapy #cancer

📺 Professor Inge Marie Svane discusses the future of personalized medicine and immunotherapy on Danish TV. On July 9, 2024, Susanne Bier and Aftenshowet on DR - Danmarks Radio invited leading cancer experts, Professor Inge Marie Svane and Professor Ulrik Niels Lassen, to share updates on Danish cancer research. They delved into the promising fields of personalized medicine and immunotherapy 🧬 👉 Catch the discussion here: https://lnkd.in/dw8cRfSD (starting at 25:25).

🌟 Pioneering Cancer Immunology Research 🌟 In the Mads Hald Andersen (MHA) group, we are at the forefront of experimental cancer immunology research with a strict focus on translating our findings into clinical applications to benefit patients 🏅 Our primary objectives: 🧬 Anti-Regulatory T Cells (Anti-Tregs): Identifying and characterizing these cells to understand their potential in cancer treatment. 💉 Immunomodulatory Vaccines: Developing vaccines targeting tumor microenvironment antigens (TMAs). 🔬 Over the past decade, we've identified circulating effector T cells, known as anti-Tregs, that recognize TMAs from immunosuppressive self-proteins like IDO, PD-L1, Arginase, and TGFβ. These anti-Tregs can directly attack cancer cells and modulate the tumor microenvironment, making it more hostile to tumors. 📊 Our research includes both pre-clinical models and investigator-initiated clinical trials aimed at harnessing the anti-cancer properties of anti-Tregs. As part of the CCIT-DK - National Center for Cancer Immune Therapy of Denmark, we thrive on the strong teamwork and diverse expertise present at our center 💪 🌍 With over 15 nationalities represented, we enjoy vibrant discussions that range from scientific breakthroughs to guessing the type of cake at our weekly Cake Club 🎂 Join us on this journey to revolutionize cancer treatment! 🙌 #CancerResearch #Immunotherapy #ClinicalTrials #TeamScience #CCITDK #dkforsk

❓ Do you want to know how CCIT - Center for Cancer Immune Therapy, Denmark is involved in #PragmaTIL as one of the TIL-producing centres? 👇Then listen to Marco Donia in the video below 👇 #CCITdk #DKForsk #ClinicalTrials #TILTherapy #CancerResearch

📣 PhD Defense, María Pérez Penco   👏 Congratulations to María Pérez Penco for successfully defending her PhD thesis, which is entitled "TGFβ-derived immune modulatory vaccine: reshaping the tumor microenvironment in pancreatic cancer."   📑 María has been part of the research at CCIT - Center for Cancer Immune Therapy, Denmark under the supervision of Mads Hald Andersen.   🙏 We would like to thank the assessment committee for their insightful evaluation and valuable feedback: ◾ María Casanova Acebes, CNIO - Spanish National Cancer Research Centre, Spain ◾ Mikkel Green Terp, Department of Molecular Medicine Syddansk Universitet - University of Southern Denmark (SDU), Denmark ◾ Chairman: Lea Klingenberg Barfod, Department of Immunology and Microbiology, Københavns Universitet - University of Copenhagen, Denmark.  

🏃♀️ 🏃♂️ Still curious about Gitte Holmen Olofsson's thoughts on the benefits of combining physical activity with #immunotherapy for patients with non-small cell lung cancer? 👉 Then listen to the podcast from #LydDoping where she discuss the subject with Eva Rudjord Therkildsen 🔊 #NSCLC #lungsm #immunotherapy #dkforsk